Lundbeck is a global pharmaceutical company specialized in brain diseases. For more than 50 years, we have been at the forefront of research within neuroscience. Our key areas of focus are alcohol dependence, Alzheimer's disease, bipolar disorder, depression/anxiety, epilepsy, Huntington's disease, Parkinson's disease, schizophrenia and stroke.
An estimated 700 million people worldwide are living with brain disease and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with brain disease we call this Progress in Mind.
Read more at www.lundbeck.com/global/about-us/progress-in-mind.
Our approximately 6... (Source: SEC reports)
DEERFIELD, Ill.--(BUSINESS WIRE)--For the third straight year, Lundbeck US, an affiliate of Danish-based
H. Lundbeck A/S, was ranked first in corporate reputation by U.S. [...]
DEERFIELD, Ill.--(BUSINESS WIRE)--For the third straight year, Lundbeck US, an affiliate of Danish-based
H. Lundbeck A/S, was ranked first in corporate reputation by U.S. [...]
DEERFIELD, Ill.--(BUSINESS WIRE)--Lundbeck today presented data at the American Epilepsy Society (AES)
Annual Meeting in Washington, D.C. that demonstrates that the Refractory
[...]
DEERFIELD, Ill.--(BUSINESS WIRE)--Lundbeck today presented data at the American Epilepsy Society (AES)
Annual Meeting in Washington, D.C. that demonstrates that the Refractory
[...]
TOKYO & VALBY, Denmark--(BUSINESS WIRE)--Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck)
announce that the two companies will initiate a third clinical [...]